BACKGROUND/AIMS: This study was aimed to determine whether host-dependent genetic factors modulate the outcome of HCV infection. METHODS: HLA class II DRB and DQB typing was performed in 184 infected patients and 200 healthy volunteers. Among the patients, 149 subjects had persistent HCV viremia (Group 1) and 35 subjects underwent spontaneous viral clearance (Group 2). Group 1 included cirrhotic patients with transfusion-acquired infections (n = 79), asymptomatic HCV carriers (n = 42), and patients with chronic hepatitis C responsive to interferon therapy (n = 28). RESULTS: Spontaneous viral clearance was associated with HLA DRB1*1104 (pc = 0.054, OR = 4.51, 95% C.I. 2.02-10.1) and HLA DQB1*0301 (pc = 0.0039, OR = 4.52, 95% C.I. 2.15-9.51). In Group 1 the haplotype DRB1*1104/DQB1*0301 was less frequent (4.8%) than in Group 2 (18.3%) (pc = 0.009, OR = 7.38, 95% C.I. 2.58-21.59). At the HLA level, cirrhotic patients were not different from asymptomatic HCV carriers and patients with interferon-induced viral clearance. In cirrhotic patients infected with genotype 1b, the DQB1*0502 allele was more frequently found in those with rapidly progressive liver damage (OR = 8.15, 95% C.I. 1.49-44.44), but the corrected p-value was not significant (pc = 0.09). CONCLUSIONS: The HLA haplotype DRB1*1104/DQB1*0301 appears to contribute to the spontaneous clearance of HCV infection. The predominance of the DQB1*0502 allele in cirrhotic patients with a rapidly progressive disease possibly reflects an influence of this allele on the progression of the HCV-related liver disease.
BACKGROUND/AIMS: This study was aimed to determine whether host-dependent genetic factors modulate the outcome of HCV infection. METHODS: HLA class II DRB and DQB typing was performed in 184 infectedpatients and 200 healthy volunteers. Among the patients, 149 subjects had persistent HCV viremia (Group 1) and 35 subjects underwent spontaneous viral clearance (Group 2). Group 1 included cirrhotic patients with transfusion-acquired infections (n = 79), asymptomatic HCV carriers (n = 42), and patients with chronic hepatitis C responsive to interferon therapy (n = 28). RESULTS: Spontaneous viral clearance was associated with HLA DRB1*1104 (pc = 0.054, OR = 4.51, 95% C.I. 2.02-10.1) and HLA DQB1*0301 (pc = 0.0039, OR = 4.52, 95% C.I. 2.15-9.51). In Group 1 the haplotype DRB1*1104/DQB1*0301 was less frequent (4.8%) than in Group 2 (18.3%) (pc = 0.009, OR = 7.38, 95% C.I. 2.58-21.59). At the HLA level, cirrhotic patients were not different from asymptomatic HCV carriers and patients with interferon-induced viral clearance. In cirrhotic patientsinfected with genotype 1b, the DQB1*0502 allele was more frequently found in those with rapidly progressive liver damage (OR = 8.15, 95% C.I. 1.49-44.44), but the corrected p-value was not significant (pc = 0.09). CONCLUSIONS: The HLA haplotype DRB1*1104/DQB1*0301 appears to contribute to the spontaneous clearance of HCV infection. The predominance of the DQB1*0502 allele in cirrhotic patients with a rapidly progressive disease possibly reflects an influence of this allele on the progression of the HCV-related liver disease.
Authors: Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington Journal: Hepatology Date: 2010-05 Impact factor: 17.425
Authors: H L Tillmann; D F Chen; C Trautwein; V Kliem; A Grundey; A Berning-Haag; K Böker; S Kubicka; L Pastucha; W Stangel; M P Manns Journal: Gut Date: 2001-05 Impact factor: 23.059
Authors: C Renou; P Halfon; S Pol; P Cacoub; E Jouve; J P Bronowicki; J P Arpurt; H Rifflet; M Picon; X Causse; V Canva; J Denis; A Tran; M Bourliére; D Ouzan; A Pariente; S Dantin; L Alric; V Cartier; M Reville; S Caillat-Zucman Journal: Gut Date: 2002-10 Impact factor: 23.059
Authors: S Mascheretti; H Hinrichsen; S Ross; P Buggisch; J Hampe; U R Foelsch; S Schreiber Journal: Clin Exp Immunol Date: 2004-05 Impact factor: 4.330
Authors: Viviana Romero; Jose Azocar; Joaquin Zúñiga; Olga P Clavijo; Daniel Terreros; Xiangjun Gu; Zaheed Husain; Raymond T Chung; Christopher Amos; Edmond J Yunis Journal: Mol Immunol Date: 2008-03-04 Impact factor: 4.407
Authors: E Spada; A Mele; A Berton; L Ruggeri; L Ferrigno; A R Garbuglia; M P Perrone; G Girelli; P Del Porto; E Piccolella; M U Mondelli; P Amoroso; R Cortese; A Nicosia; A Vitelli; A Folgori Journal: Gut Date: 2004-11 Impact factor: 23.059